VivoSeq
Other

PK/PD

0

Pipeline Programs↗

5

Active Trials↗

21

Companies Involved↗

PK/PD is an early-stage landscape with 0 programs across 21 companies. The most active players are Portola Pharmaceuticals, iN Therapeutics Co., Ltd., Haisco Pharmaceutical Group Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

98/100

Attrition Rate

2/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Portola Pharmaceuticals

0 programs

PreclinicalI

iN Therapeutics Co., Ltd.

0 programs

PreclinicalHaisco Pharmaceutical Group Co., Ltd. logo

Haisco Pharmaceutical Group Co., Ltd.

0 programs

PreclinicalBayer logo

Bayer

0 programs

PreclinicalP

PhaseBio Pharmaceuticals Inc.

0 programs

PreclinicalX

Xiamen Amoytop Biotech Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

49

clinical trials

Completed39 · 80%
Unknown status4 · 8%
Recruiting3 · 6%
Not yet recruiting2 · 4%
Terminated1 · 2%

Clinical Trials

Trial Activity

49 trials

Safety, Tolerability, and PK/PD of CIGB-814 in Chinese Health Participants
Recruiting·—·Phase 1·NCT07182656·70 enrolled
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
Recruiting·OOriCell Therapeutics Co., Ltd.·Phase 1·NCT06271252·81 enrolled
A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients.
Recruiting·IiN Therapeutics Co., Ltd.·Phase 1·NCT06218784·64 enrolled
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants..
Not yet recruiting·XXiamen Amoytop Biotech Co., Ltd.·Phase 1·NCT07408908·48 enrolled
A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A
Not yet recruiting·AAddpharma Inc.·Phase 1·NCT06916130·48 enrolled
Safety, Tolerability,PK/PD, Food Effect of Single and Multiple Ascending Doses of HSK31858 in Healthy Volunteers
Completed·Haisco Pharmaceutical Group Co., Ltd. logoHaisco Pharmaceutical Group Co., Ltd.·Phase 1·NCT05663593·74 enrolled
Nifedipine (Adalat CR, BAY A1040) High Dose PK/PD Study
Completed·Bayer logoBayer·Phase 2·NCT00768560·35 enrolled
Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF
Completed·PPhaseBio Pharmaceuticals Inc.·Phase 2·NCT02808585·29 enrolled
Pharmacokinetic/Pharmacodynamic (PK/PD) Study Evaluating Pegfilgrastim Hospira Compared to Neulasta (Amgen) in Healthy Volunteers
Completed·Pfizer logoPfizer·Phase 1·NCT00938678·71 enrolled
CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study
Completed·Biogen logoBiogen·Phase 1·NCT00412412·34 enrolled
The Multiple Dose of PK/PD Study of SHR2285 Tablets in Healthy Subjects
Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04229433·36 enrolled
Pharmacokinetics/Pharmacodynamics (PK/PD) of Cangrelor
Completed·Novartis logoNovartis·Phase 1·NCT00102674·40 enrolled
The PK/PD Study of SHR2285 Tablets in Healthy Subjects
Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT03769831·28 enrolled
A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121
Completed·AAddpharma Inc.·Phase 1·NCT06025773·24 enrolled
PK/PD Study of YZJ-1139
Completed·SShanghai Haiyan Pharmaceutical Technology Co., Ltd.·Phase 1·NCT06685341·20 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)